TUESDAY, MAY 10, 2016
INDUSTRY SYMPOSIUM 1 – THE EVOLVING MENINGOCOCCAL LANDSCAPE: OPTIMAL VACCINATION STRATEGIES
Tuesday, May 10, 08:30-10:00 , Hall B
INDUSTRY SYMPOSIUM SUPPORTED BY PFIZER GLOBAL
Current Trends In Meningococcal Disease Epidemiology Around The Globe In The Genomic Surveillance Era
Marco Sáfadi, Brazil
The Public Health Authority: Perspective And Recommendations
David Salisbury, UK
Is It Reasonable To Fear A Vaccine-Preventable Disease?
Federico Martinón-Torres, Spain
******
INDUSTRY SYMPOSIUM 2 – AN UPDATE ON RSV INFECTION: ARE WE MAKING PROGRESS?
Tuesday, May 10, 10:30-12:00 , Hall A
INDUSTRY SYMPOSIUM SUPPORTED BY ABBVIE
10:30 – 10:35 Welcome / Introduction to An Update on RSV Infection: Are We Making Progress?
Octavio Ramilo, USA
10:35– 11:00 Understanding RSV pathogenesis: Implications for disease severity
Asuncion Mejias, USA
11:00 – 11:25 RSV and Pneumonia: The clinical evidence
David Greenberg, Israel
11:25– 11:50 What is in the pipeline: New therapies for RSV infection
Octavio Ramilo, USA
11:50-12:00 Questions & Answers
Closing remarks by Faculty and Audience
******
INDUSTRY SYMPOSIUM 3 – INNOVATION IN RSV PREVENTION: THE PROMISE OF MATERNAL IMMUNIZATION
Tuesday, May 10, 13:00-14:30 , Hall A
INDUSTRY SYMPOSIUM SUPPORTED BY NOVAVAX
13:00 – 13:20 Burden of RSV Disease in Infants
Matthew Snape, UK
13:20 – 13:40 Maternal Immunization: Lessons Learned from the UK Pertussis Experience
Paul Heath, UK
13:40 – 14:00 Barriers in Maternal Immunization and Prevention of Perinatal Infection
Pierre Van Damme, Belgium
14:00 – 14:20 RSV F Nanoparticle Vaccine: 6-month Follow-Up Results of a Phase 2 Clinical Trial to Protect Infants via Maternal Immunization
Allison August, USA
14:20 – 14:30 Questions & Answers and Panel Discussion
******
INDUSTRY SYMPOSIUM 4 – PERTUSSIS RESURGENT: MAXIMIZING PROTECTION STRATEGIES IN THE 21ST CENTURY
Tuesday, May 10, 14:45-16:15 , Hall A
INDUSTRY SYMPOSIUM SUPPORTED BY MEDSCAPE
Welcome and Introduction: Confronting Pertussis in the 21st Century
Federico Martinón-Torres, Spain
The Landscape of Pertussis Across the Spectrum of Infection: Who? Where? When?
Terry Nolan, Australia
Pertussis Immunization: Optimizing the Tools We Have
Carl Heinz Wirsing von König, Germany
Strategies for Protecting the Most Vulnerable Children
Gayatri Amirthalingam, UK
Panel Discussion: Translating Strategies Into Clinical Practice
Participant Q&A
Concluding RemarksFederico Martinón-Torres, Spain
******
INDUSTRY SYMPOSIUM 5 – NEW HORIZONS IN HPV VACCINATION
Tuesday, May 10, 16:45-18:15 , Hall A
INDUSTRY SYMPOSIUM SUPPORTED BY SANOFI PASTEUR MSD
Chairman: M. Stanley, UK
Introduction
M. Stanley, UK
HPV vaccination: extending the horizons
X. Castellsague, Spain
- Burden of HPV-related diseases in EU
X. Castellsague, Spain- New HPV vaccine for adolescent vaccination
X. Castellsague, Spain
All/ X. Castellsague, Spain
Vaccinating girls and boys: the pioneer steps in Europe
M. Stanley, UK
- Achievements and Challenges in EU
M. Stanley, UK
- Boys vaccination in Europe
P. Bonanni, Italy, OE. Iversen, Norway
- Questions & Answers & Chair's Closing Remarks
All/ M. Stanley, UK
******
INDUSTRY SYMPOSIUM 6 – INFLUENZA PREVENTION - CAN THE LATEST EVIDENCE FROM THE UK CHILDHOOD IMMUNISATION PROGRAMME IMPACT EUROPEAN POLICIES?
Tuesday, May 10, 18:30-20:00 , Hall A
INDUSTRY SYMPOSIUM SUPPORTED BY ASTRAZENECA
18:30 Introduction to paediatric influenza vaccination and overview of current policy landscape
Terho Heikkinen, Finland (Chairman)
18:50 Vaccinating children against influenza: Lessons from the Hutterite community on herd effect
Mark Loeb, Canada
19:10 Outcomes of the paediatric influenza national immunisation programme in England
David Salisbury, UK
19:30 Debate with the audience – Can the latest evidence impact European vaccination policies?
All faculty and audience
19:55 Concluding remarks
Chairman
******
INDUSTRY SYMPOSIUM 7 – CHOICE IN THE ERA OF PNEUMOCOCCAL
CONJUGATE VACCINES: WEIGHING THE DATA, CLARIFYING THE ISSUES
Tuesday, May 10, 20:15 – 21:45, Hall A
INDUSTRY SYMPOSIUM SUPPORTED BY MEDSCAPE
Welcome And Introduction: Pediatric Pneumococcal Disease
Immunization
David Goldblatt, UK
Weighing The Data: Analyzing the Epidemiology of Pneumococcal Disease
Asgeir Haraldsson, Iceland
The PCV Era: Evolution of Protection
Marco A.P. Sáfadi, Brazil
Clarifying the Issues: PCV Impact on Disease Burden
Arto Palmu, Finland
Panel Discussion
Participant Q&A
Concluding Remarks
David Goldblatt, UK
******
Wednesday, May 11, 2016
INDUSTRY SYMPOSIUM 8 - MENINGOCOCCAL DISEASE PREVENTION: INTRODUCTION OF NEW VACCINATION STRATEGIES IN UK
Wednesday, May 11, 08:30-10:00 , Hall A
The timeslot of this Industry Symposium has been offered by GSK to Public Health England. Agenda and content of presentations have been developed independently by Public Health England, with no input from GSK.
8.30 Epidemiology of Meningococcal Disease in the UK
Shamez Ladhani, UK
8.45 The MenB Immunisation Programme
Joanne Yarwood, UK
9.00 Attitudes to Meningococcal Disease & Vaccination
Helen Bedford, UK
9.15 The role of Public Health England Meningococcal Reference Unit
Ray Borrow, UK
9.30 Controlling the MenW outbreak
Helen Campbell, UK
9.45 Discussion and debate involving Faculty and Audience
******
INDUSTRY SYMPOSIUM 9 – COMBINED PAEDIATRIC VACCINES: FROM THE MANUFACTURING SITE TO THE NETWORKING WEB SIDE
Wednesday, May 11, 10:30-12:00 , Hall A
INDUSTRY SYMPOSIUM SUPPORTED BY SANOFI PASTEUR MSD
10:30-10:45 Introduction: the public health benefits of combined paediatric vaccines
Pierre van Damme, Belgium (Chair)
10:45-11:05 Manufacturing: overcoming the challenges for combined paediatric vaccines
Emmanuel Vidor, France
11:05-11:25 Daily practice: addressing the preferences of health care professionals for combined paediatric vaccines beyond their intrinsic performances
Andrew Lloyd, UK
11:25-11:45 On the web: getting the most from online resources and social networks
Gary Finnegan, Ireland
11:45-12:00 Concluding remarks
Pierre van Damme, Belgium (Chair)
******
INDUSTRY SYMPOSIUM 10 - THE GROWING WORLDWIDE EVIDENCE FOR PCVS IN INFANTS AND CHILDREN: FROM CLINICAL OUTCOMES TO PUBLIC HEALTH BENEFITS
Wednesday, May 11, 13:00-14:30 , Hall A
INDUSTRY SYMPOSIUM SUPPORTED BY PFIZER EU
Chair: Mike Sharland, UK
Co-chair: Heinz-Josef Schmitt, France
13:00 Welcome
Heinz-Josef Schmitt, France
13:10 Introduction and survey
Mike Sharland, UK
13:15 Update on the public health impact of PCV13
Mike Sharland, UK
13:35 What has PCV implementation taught us about impact on mucosal diseases?
Ron Dagan, Israel
14:05 What should be considered to maximise impact of pneumococcal vaccination?
Panel discussion - All
